Adherence to tamoxifen over the five-year course.

Department of Epidemiology, Boston University School of Public Health, Boston, MA 02118, USA.
Breast Cancer Research and Treatment (Impact Factor: 4.2). 10/2006; 99(2):215-20. DOI: 10.1007/s10549-006-9193-0
Source: PubMed

ABSTRACT To estimate the proportion of older women who fail to complete 5 years of tamoxifen therapy and to identify predictors of non-adherence.
We followed 462 women 65-years-old or older with stage I-IIIA breast cancer diagnosed in four US regions between 1996 and 1999 and who initiated tamoxifen therapy. We interviewed patients annually to assess tamoxifen adherence and collected information about predictors of adherence by medical record review, patient interview, and physician questionnaire.
Thirty-one percent of patients who started tamoxifen failed to complete the recommended 5-year course. Patients who had initial severe side effects [hazard ratio (HR) per side effect=1.2, 95% confidence interval (CI) 0.97, 1.5] or developed them (HR per new side effect=1.3, 95% CI 1.0, 1.6) were more likely to discontinue. Patients with more prescription medications at baseline were less likely to discontinue (HR per baseline prescription equaled 0.90, 95% CI 0.81, 0.99), whereas patients who added a prescription were more likely to discontinue (HR per new prescription equaled 1.2, 95% CI 1.0, 1.4). Patients with positive views of tamoxifen at baseline (HR for a 10-point higher score=0.93, 95% CI 0.83, 1.0) and an improving view over follow-up (HR for a 10-point positive change=0.93, 95% CI 0.87, 1.0) were less likely to discontinue.
Five years of tamoxifen confers a significant benefit beyond 1-2 years of tamoxifen, so physicians should ask patients about side effects, other prescriptions, and beliefs about tamoxifen and should educate them about the benefits of completing adjuvant therapy.

  • Source
    • "There is also evidence of therapy-related factors being associated with adherence. Research suggests that adverse events, more complex treatment regimens, and higher cost of medication are associated with non-adherence to AET [14] [15] [16] [17]. However, much less is known about provider level factors that are associated with adherence. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective Breast cancer incidence and mortality are declining due to improvements in early detection and treatment. One advance in treatment is the development of adjuvant endocrine therapy (AET) for women with hormone receptor positive breast cancer. Despite strong evidence linking AET to better health outcomes, AET adherence continues to be suboptimal. This study tests the hypothesis that patient beliefs about medication mediate the relationship between frequency of physician communication and AET adherence. Methods This cross-sectional study utilizes data from patient self-report and medical chart abstraction (N = 200). Survey measures included frequency of physician communication, patient beliefs about medicine, AET adherence, and demographic characteristics. Results Necessity beliefs mediated the relationship between frequency of physician communication and medication adherence (necessity beliefs β = .18, p < 05; physician communication β = .13, p > 05). There was no evidence of medication concerns mediating the relationship between frequency of physician communication and medication adherence. Discussion More frequent physician communication that shapes what patients believe about AET importance may be associated with greater AET adherence; however, frequent physician communication that shapes patient concerns about side effects may not be associated with greater AET adherence. Practice Implications Research is needed to enhance understanding of the type of physician communication that is most consistently associated with patient beliefs about medication and AET adherence.
    Patient Education and Counseling 04/2014; 95(1). DOI:10.1016/j.pec.2013.12.019 · 2.60 Impact Factor
  • Source
    • "The most robust data come from studies of women with breast cancer taking oral hormonal therapy (Banning, 2012) and patients with CML (Jabbour et al., 2012) taking imatinib. Seminal work in breast cancer (Fink et al., 2004; Hershman et al., 2010; Lash et al., 2006; Partridge et al., 2008; 2003; Waterhouse et al., 1993) has provided the basis for research examining adherence to targeted OAMs, particularly for " chronically critically ill " individuals with cancer (e.g., lung cancer, renal cell carcinoma). Research concerning adherence for women with breast cancer taking oral hormonal therapies has been well summarized; therefore, in this review, we focus on studies of adherence to molecularly targeted OAMs for persons with cancer (Table 3). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The use of targeted oral anticancer medications (OAMs) is becoming increasingly prevalent in cancer care. Approximately 25-30% of the oncology drug pipeline involves oral agents and there are now over 50 OAMs approved by the Food and Drug Administration. This change represents a major shift in management of patients with cancer from directly observed, intermittent intravenous therapy to self-administered, oral chronic therapy. The increased prevalence of OAMs raises the issue of adherence in oncology, including understanding the challenges of adherence to OAMs. This review focuses on studies of adherence for patients taking molecularly targeted OAMs for breast cancer, chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GIST), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). We then discuss barriers to adherence and studies performed to date testing interventions for improving adherence. Finally, we discuss future areas of investigation needed to define and improve adherence to OAMs in targeted therapy for cancer.
    Discovery medicine 04/2013; 15(83):231-41. · 3.50 Impact Factor
  • Source
    • "progression and death (Early Breast Cancer Trialist' Collaborative Group (EBCTCG), 2005; Lash et al, 2006). Aromatase inhibitors have demonstrated superiority to tamoxifen, whether alone or in sequence with tamoxifen in postmenopausal women with BC (Mouridsen et al, 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aims: To compare different methods in order to assess adherence and persistence with oral endocrine therapy in women diagnosed with breast cancer (BC) in Catalonia. Materials and methods: This study covered all women newly diagnosed with stage I, II or IIIa BC and positive hormone receptors at six hospitals in Catalonia (Spain) in 2004. Adherence was assessed on the basis of physician report and patient self-report using a telephone questionnaire. Persistence was measured by refill prescriptions. We used the Kappa index to compare adherence measures and logistic regression to evaluate adherence-related risk factors. Results: The study covered a total of 692 women. Adherence ranged from 92% (self-report) to 94.7% (physician report), depending on the measure used; persistence was 74.7% at 5 years of follow-up. Low concordance between measures was observed (Kappa range: 0.018–0.267). Patients aged 50–74 years showed higher adherence than those aged <50 years. Adherence was also associated with: adjuvant chemotherapy and sequential hormonal therapy. Conclusions: Concordance between the different measures was remarkably low, indicating the need for further research. Adherence is an issue in the management of BC patients taking oral drugs, and should be assessed in clinical practice.
    British Journal of Cancer 09/2012; 107(8):1249-56. DOI:10.1038/bjc.2012.389 · 4.82 Impact Factor